Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

conomic benefits from developing OGX-011 are all forward-looking statements. The potential risks and uncertainties include, among others, that clinical results will not be maintained in final data analysis, that current or future clinical trials will not be successful or confirm the results of earlier studies, that OncoGenex may not realize the anticipated economic benefits from developing OGX-011 on its own, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of OncoGenex. OncoGenex undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400, scormack@oncogenex.ca; OncoGenex Investor and Media Contact: Jason Spark, Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com


'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... executives hold high expectations that information technology will reduce ... however.  Earley & Associates, the nation,s foremost information management ... series titled Digitization of the Healthcare Industry ... on Wednesday, May 4 from 1-2 p.m. ...
... 3, 2011 Talecris Biotherapeutics Holdings Corp. (NASDAQ: ... Chapel Hill, N.C., where four proposals were submitted to, and ... the company,s Board of Directors to hold office for a ... and until their successors are elected and qualified. The three ...
... Inc. (Nasdaq: NVAX ) will report financial results ... 2011, before the U.S. financial markets open.  The announcement will ... Stanley C. Erck, President and Chief Executive Officer, and other ... The webcast and conference call will be available ...
Cached Biology Technology:Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 2Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 3Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting 2
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Pathogens , Francisella tularensis , the cause of ... is considered a potential biological weapon because it is readily ... in humans. While a live attenuated vaccine strain has ... to understand the basis for its attenuated virulence. In ...
... Universitt Mnchen (TUM) under Prof. Peter Schieberle and at the ... edible fats and oils: Lard, butterfat, rapeseed oil and olive ... ate 500 grams of low-fat yoghurt enriched with one of ... supplement to their normal diet. "Olive oil had the ...
... series across both genders continue to remain alarmingly low ... patient education and increased public vaccine financing programs are ... Texas Medical Branch (UTMB). The researchers report ... published in Cancer, Human Vaccines & Immunotherapeutics ...
Cached Biology News:News tips from the journal mBio®, volume 4, issue 1 2Olive oil makes you feel full 2HPV vaccine trends point to failures in patient education, vaccine programs 2
... template is designed to allow kanamycin/neomycin ... It combines a prokaryotic promoter (gb2) ... E.coli with a eukaryotic promoter (PGK) ... cells. The prokaryotic promoter gb2 is ...
... The loxP-PGK-gb2-neo-loxP template is designed ... and eukaryotic cells. The loxP-PGK-gb2-neo-loxP ... which combines a prokaryotic promoter (gb2) ... E.coli with a eukaryotic promoter (PGK) ...
... This depletion cocktail is ... T cells from suspensions of ... separated using the StemSep (or ... cell selection system. The CD4+ ...
Standard Fluka For microscopy (Hist.) redox indicator...
Biology Products: